SCHEMBL5260372

SCHEMBL5260372

O=C(O)c1ccc(C(=O)Cc2ccccc2)cc1

nearest known ligand 0.89

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 3/20 0.89
MAPT P10636 1/20 0.71
L3MBTL1 Q9Y468 1/20 0.71
STS P08842 1/20 0.57
RAB9A P51151 2/20 0.56
GAA P10253 1/20 0.56
TSHR P16473 3/20 0.54
DAO P14920 1/20 0.54
NAPRT Q6XQN6 1/20 0.54
CES2 O00748 2/20 0.54
CES1 P23141 2/20 0.54
AKR1B1 P15121 1/20 0.54
NR4A1 P22736 1/20 0.53
NR4A2 P43354 1/20 0.53
NR4A3 Q92570 1/20 0.53
PLAU P00749 1/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
S1PR5 Q9H228 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13381371 0.94 SRD5A2 (0.79) SRD5A2MAPTL3MBTL1STSRAB9A
SCHEMBL7129800 0.93 MAPT (0.80) SRD5A2MAPTL3MBTL1STSRAB9A
SCHEMBL13381377 0.91 SRD5A2 (0.74) SRD5A2MAPTL3MBTL1STSRAB9A
Benzophenone SCHEMBL28256421 0.90 SRD5A2 (0.93) SRD5A2MAPTL3MBTL1STSRAB9A
Terephthalic Acid SCHEMBL19469307 0.89 SRD5A2 (0.72) SRD5A2MAPTL3MBTL1STSRAB9A
SCHEMBL24800 0.89 MAPT (0.73) SRD5A2MAPTL3MBTL1STSRAB9A
SCHEMBL8033816 0.87 SRD5A2 (0.89) SRD5A2MAPTL3MBTL1STSRAB9A
Bicarbonate SCHEMBL28984888 0.86 MAPT (0.70) SRD5A2MAPTL3MBTL1STSRAB9A
SCHEMBL4282905 0.86 MAPT (0.70) SRD5A2MAPTL3MBTL1STSRAB9A
Water SCHEMBL20527670 0.86 MAPT (0.70) SRD5A2MAPTL3MBTL1STSRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108884242-B Prepreg product and composite product comprising fibres and a liquid crystalline thermoset precursor 阿罗特罗皮卡科技公司 2021-11-26 CN disclosed
CN-111378145-A Force-induced response multiphase supramolecular block polymer 翁秋梅 2020-07-07 CN disclosed
CN-111378144-A Force-induced response supramolecular polymer 翁秋梅 2020-07-07 CN disclosed
US-9447028-B2 Therapeutic aryl-amido-aryl compounds and their use KING'S COLLEGE LONDON (GB) 2016-09-20 US disclosed
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2016-02-11 US disclosed
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed
US-7750151-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2010-07-06 US disclosed
US-7750151-B2 Inhibitors of Akt activity MERCK SHARP & DOHME CORP. (US) 2010-07-06 US disclosed
US-20080280899-A1 Inhibitors of Akt Activity MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed
US-20080280899-A1 Inhibitors of Akt Activity MERCK SHARP & DOHME CORP. 2008-11-13 US disclosed
EP-1496896-A4 INHIBITORS OF AKT ACTIVITY MERCK & CO INC (US) 2007-10-31 EP disclosed
US-7223738-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2007-05-29 US disclosed
US-7223738-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2007-05-29 US disclosed
US-7223738-B2 Inhibitors of Akt activity MERCK & CO., INC. (US) 2007-05-29 US disclosed
US-20050222155-A1 Inhibitors of akt activity MERCK SHARP & DOHME CORP. 2005-10-06 US disclosed
EP-1496896-A1 INHIBITORS OF AKT ACTIVITY Merck & Co., Inc. (US) 2005-01-19 EP disclosed
WO-2003086394-A1 INHIBITORS OF AKT ACTIVITY MERCK & CO., INC. (US) 2003-10-23 WO disclosed
CN-86107627-A The preparation method of novel 4-benzyl-1-(2H)-phthalazinone derivatives 1987-07-15 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG SRD5A2 2231/4885MAPT 150/4885L3MBTL1 2847/4885
US-20080280899-A1 Inhibitors of Akt Activity AKT1, AKT2, AKT3 SRD5A2 3698/4885MAPT 1843/4885L3MBTL1 3591/4885
US-20050222155-A1 Inhibitors of akt activity AKT1, AKT2, AKT3 SRD5A2 3691/4885MAPT 2492/4885L3MBTL1 2879/4885
US-20160039747-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG SRD5A2 2231/4885MAPT 150/4885L3MBTL1 2847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.